Skin appearance. Before (A) and after (B) 12 weeks of alemtuzumab treatment in patients with advanced erythrodermic MF/SS. Erythroderma, which was present all over the body and caused severe itching and repeated infections, responded gradually to alemtuzumab therapy, and the patient went into unmaintained CR that lasted for 18 months.